One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer

Published:2015-06 Issue:5 Volume:30 Page:195-199
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Jadvar Hossein¹,Challa Sudha¹,Quinn David I.²,Conti Peter S.¹

Affiliation:

1. Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.

2. Division of Cancer Medicine, Department of Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2014.1802

Reference21 articles.

1. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients

2. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer

3. New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer

4. Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Micellar solution of [223Ra]RaCl2: Reaching renal excretion, potent efficacy in osteoblastic osteosarcoma in PDX model, biochemistry alterations and pharmacokinetics;International Journal of Pharmaceutics;2024-03

2. Radiochemistry: A Hot Field with Opportunities for Cool Chemistry;ACS Central Science;2023-11-14

3. Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges;World Journal of Nuclear Medicine;2022-09-02

4. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial;European Journal of Cancer;2022-09

5. Targeted Radionuclide Therapy and Immunotherapy of Metastatic Prostate Cancer;Nuclear Medicine and Immunology;2021-11-25